About event
When we think of resistance to cancer therapies, we prevalently think of gene mutations. However, recent findings highlight the crucial role of non-genetic adaptation mechanisms that come before the genetic resistance. In our laboratory, we have described for the first time a non-genetic adaptation mechanism to targeted therapy in chronic lymphocytic leukemia. By dissecting the molecular pathways involved, we provide insights into potential therapeutic strategies to counteract this adaptive resistance, offering new options to improve patient outcomes.
